Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy
- 12 November 2008
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 15 (12), 1371-1379
- https://doi.org/10.1111/j.1468-1331.2008.02318.x
Abstract
A pilot study of high dose coenzyme Q(10) (CoQ(10))/vitamin E therapy in Friedreich's ataxia (FRDA) patients resulted in significant clinical improvements in most patients. This study investigated the potential for this treatment to modify clinical progression in FRDA in a randomized double blind trial. Fifty FRDA patients were randomly divided into high or low dose CoQ(10)/ vitamin E groups. The change in International Co-operative Ataxia Ratings Scale (ICARS) was assessed over 2 years as the primary end-point. A post hoc analysis was made using cross-sectional data. At baseline serum CoQ(10) and vitamin E levels were significantly decreased in the FRDA patients (P < 0.001). During the trial CoQ(10) and vitamin E levels significantly increased in both groups (P < 0.01). The primary and secondary end-points were not significantly different between the therapy groups. When compared to cross-sectional data 49% of all patients demonstrated improved ICARS scores. This responder group had significantly lower baseline serum CoQ(10) levels. A high proportion of FRDA patients have a decreased serum CoQ(10) level which was the best predictor of a positive clinical response to CoQ(10)/vitamin E therapy. Low and high dose CoQ(10)/vitamin E therapies were equally effective in improving ICARS scores.Keywords
This publication has 26 references indexed in Scilit:
- Frataxin Acts as an Iron Chaperone Protein to Modulate Mitochondrial Aconitase ActivityScience, 2004
- Role of Oxidative Damage in Friedreich's AtaxiaNeurochemical Research, 2004
- Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxiaHuman Molecular Genetics, 2002
- Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: An in vivo 31P magnetic resonance spectroscopy studyCardiovascular Research, 2001
- Oxidative stress in patients with Friedreich ataxiaNeurology, 2000
- Clinical, biochemical and molecular genetic correlations in Friedreich's ataxiaHuman Molecular Genetics, 2000
- Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxiaProceedings of the National Academy of Sciences of the United States of America, 1999
- Frataxin is Reduced in Friedreich Ataxia Patients and is Associated with Mitochondrial MembranesHuman Molecular Genetics, 1997
- Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxiaNature Genetics, 1997
- FRIEDREICH'S ATAXIA: A CLINICAL AND GENETIC STUDY OF 90 FAMILIES WITH AN ANALYSIS OF EARLY DIAGNOSTIC CRITERIA AND INTRAFAMILIAL CLUSTERING OF CLINICAL FEATURESBrain, 1981